The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

However, this came as good news for investors in AbbVie’s peer Bristol Myers Squibb (NYSE:BMY) as the company recently secured the U.S. FDA approval for its schizophrenia drug Cobenfy ...

THURSDAY, Nov. 14, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of ...

Gain insight on Rigel Pharmaceuticals, AbbVie and more in the latest Market Talks covering the Health Care sector.

Bristol-Myers Squibb has also been making strides in clinical trials. Notably, the FDA approved Cobenfy, a new treatment for schizophrenia, and the company reported promising news about milvexian.

Bristol-Myers Squibb has also been making strides in clinical trials. Notably, the FDA approved Cobenfy, a new treatment for schizophrenia, and the company reported promising news about milvexian.

The US could start catching up to Europe on biosimilars if the FDA removed the need for switching ... In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel ...